HDAC9 and B-cell non-Hodgkin lymphoma: In this study, we show that MPT0E028 possesses a more potent inhibitory effect against HDACs and greater ability in targeting Akt compared with the HDAC inhibitor vorinostat (SAHA) in human B-cell lymphoma cells.